首頁 > 市場調查報告書 > 食物/飲料

食品添加劑機能性食品

市場調查報告書

商品編碼

1319215

全球人乳低聚醣市場 - 2023-2030 年

Global Human Milk Oligosaccharides Market - 2023-2030

出版日期: 2023年07月31日 | 出版商:

DataM Intelligence | 英文 102 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概述

2022 年，全球人乳低聚醣(HMO) 市場價值為1.965 億美元，預計到2030 年將實現利潤豐厚的成長，達到8.505 億美元。在2023-2030 年的預測期內，該市場的年複合成長率將達到20.1%。

眾所周知，HMO 可支持免疫系統、促進腸道健康並有助於認知發展。隨著醫療保健專業人員和消費者的認知不斷提高，各年齡段（包括嬰兒、兒童和成人）對基於HMO 的產品的需求也在不斷增加。

HMO 被認為是益生元，因為它們能選擇性地刺激腸道有益菌的生長。 HMO 的益生特性越來越受到市場的關注，越來越多的研究聚焦於HMO 對腸道微生物群的影響以及相關的健康益處。對腸道-大腦軸的認知以及腸道健康在整體健康中的作用進一步推動了人們對作為益生元成分的HMO 的興趣。

市場動態

嬰兒人口成長推動人乳低聚醣(HMO) 市場成長

全球出生率不斷上升。據聯合國統計，每天有385,000 名新生兒出生。每年新生兒總數超過1.4 億。出生率的提高導致需要適當營養的嬰兒數量增加。隨著父母越來越重視嬰兒的營養需求，對嬰兒配方奶粉和其他嬰兒營養產品（包括富含HMO 的產品）的需求也在不斷成長。

嬰兒餵養方式發生了轉變，特別是在母乳喂養率歷來較低的地區。城市化、生活方式的改變以及越來越多的職業母親等因素促使包括使用嬰兒配方奶粉在內的替代餵養方式增多。因此，人們對配方奶粉產品的要求越來越高，要求其成分和益處與母乳接近，其中包括添加HMO。

對HMO 優點的認知推動人乳低聚醣(HMO) 市場成長

HMO 是母乳中的天然成分，已被證明對嬰兒健康有諸多益處。它們有助於健康腸道微生物群的發育，而腸道微生物群在消化、營養吸收和免疫系統發育中起著至關重要的作用。 HMO 還能降低感染、過敏和某些疾病的風險。隨著人們對這些益處的認知不斷加深，家長和醫療保健專業人員積極尋找以HMO 為基礎的產品，為嬰兒提供最佳營養和健康支持。

人們越來越認知到健康的腸道微生物群對整體健康的重要性。 HMO 可作為益生元，有選擇性地滋養腸道有益菌，如雙歧桿菌。它們能促進這些有益細菌的生長，同時抑制有害病原體的生長。隨著研究不斷揭示腸道微生物群在包括免疫功能和認知發展在內的各方面健康中的重要作用，人們對HMO 作為支持健康腸道微生物群的一種手段的認知和需求也在不斷成長。

監管和知識產權問題可能阻礙人乳低聚醣（HMO）市場的發展

食品和膳食補充劑產品中使用的HMO 必須遵守美國食品藥品管理局(FDA) 和歐洲食品安全局(EFSA) 等管理機構制定的監管要求。這些法規對與基於HMO 的產品相關的安全性、標籤和健康聲明等方面做出了規定。滿足這些法規要求可能既複雜又耗時，需要大量的資源和專業知識。難以獲得監管部門的批准可能會延誤產品上市，或限制基於HMO 的產品進入市場。

知識產權在創新和市場競爭中發揮著至關重要的作用。公司投入研發力量，以創造新穎的HMO 組合物、生產流程和應用。獲得專利可以保護這些創新，並為公司提供獨占性和競爭優勢。然而，如果存在重大專利糾紛、法律挑戰或專有技術使用限制，知識產權問題可能會阻礙市場成長。這會限制新企業的進入，阻礙基於HMO 的創新產品的開發。

COVID-19 影響分析

COVID-19 分析包括COVID 前情景、COVID 情景和COVID 後情景，以及定價動態（包括疫情期間和疫情后的定價變化，並與COVID 前情景進行比較）、供求光譜（由於貿易限制、封鎖和後續問題而導致的供需變化）、政府計劃（政府機構為振興市場、部門或行業而採取的計劃）和製造商戰略計劃（此處將涵蓋製造商為緩解COVID 問題而採取的措施）。

Market Overview

The Global Human Milk Oligosaccharides (HMO) Market was valued US$ 196.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 850.5 million by 2030. The market is growing at a CAGR of 20.1% during the forecast period 2023-2030.

HMOs are known to support the immune system, promote gut health, and aid in cognitive development. As awareness spreads among healthcare professionals and consumers, there is a rising demand for HMO-based products across various age groups, including infants, children, and adults.

HMOs are considered prebiotics as they selectively stimulate the growth of beneficial gut bacteria. The prebiotic properties of HMOs are gaining attention in the market, with increased research focusing on their impact on gut microbiota and associated health benefits. The understanding of the gut-brain axis and the role of gut health in overall well-being further drive the interest in HMOs as prebiotic ingredients.

Market Dynamics

The Rising Infant Population is Driving the Market Growth of Human Milk Oligosaccharides (HMO)

The global birth rate has been increasing globally. According to the UN 385,000 newborns are born every day. That totals more than 140 million annually. This higher birth rate leads to a larger population of infants requiring proper nutrition. As parents become more conscious of the nutritional needs of their infants, there is a growing demand for infant formula and other infant nutrition products, including those enriched with HMOs.

There has been a shift in infant feeding practices, particularly in regions where breastfeeding rates have historically been low. Factors such as urbanization, changing lifestyles, and the increasing number of working mothers contribute to the rise in alternative feeding methods, including the use of infant formula. As a result, there is an increased demand for formula products that closely resemble the composition and benefits of human breast milk, which includes the incorporation of HMOs.

Awareness of HMO Benefits is Driving Human Milk Oligosaccharides (HMO) Market Growth

HMOs are natural components found in human breast milk and have been shown to provide numerous health benefits to infants. They support the development of healthy gut microbiota, which plays a crucial role in digestion, nutrient absorption, and immune system development. HMOs are also associated with reduced risks of infections, allergies, and certain diseases. As awareness of these benefits grows, parents and healthcare professionals actively seek out HMO-based products to provide optimal nutrition and support the health of infants.

There is increasing recognition of the importance of healthy gut microbiota in overall well-being. HMOs act as prebiotics, selectively nourishing beneficial gut bacteria, such as Bifidobacteria. They promote the growth of these beneficial bacteria while inhibiting the growth of harmful pathogens. As research continues to unveil the significant role of the gut microbiota in various aspects of health, including immune function and cognitive development, the awareness and demand for HMOs as a means to support healthy gut microbiota is growing.

Regulatory and Intellectual Property Issues can Hamper the Growth of the Human Milk Oligosaccharides (HMO) Market

HMOs used in food and dietary supplement products must adhere to regulatory requirements set by governing bodies, such as the U.S. Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA). These regulations govern aspects such as safety, labeling, and health claims associated with HMO-based products. Meeting these regulations can be complex and time-consuming, requiring substantial resources and expertise. Difficulties in obtaining regulatory approvals may delay product launches or limit the market entry of HMO-based products.

Intellectual property rights play a crucial role in innovation and market competition. Companies invest in research and development efforts to create novel HMO compositions, manufacturing processes, and applications. Obtaining patents protects these innovations and provides companies with exclusivity and competitive advantage. However, intellectual property issues can hamper market growth if there are significant patent disputes, legal challenges, or restrictions on the use of proprietary technologies. This can limit the entry of new players and hinder the development of innovative HMO-based products.

COVID-19 Impact Analysis

The COVID-19 Analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with Pricing Dynamics (Including pricing change during and post-pandemic comparing it to pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), Government Initiatives (Initiatives to revive market, sector or Industry by Government Bodies) and Manufacturers Strategic Initiatives (What manufacturers did to mitigate the COVID issues will be covered here).

Segment Analysis

The global human milk oligosaccharides (HMO) market is segmented based on product, type, application, and region.

Abundance of 2'-Fucosyllactose (2'FL) in Human Milk

The global Human Milk Oligosaccharides (HMO) market has been segmented by Infant Formula, Dietary Supplements, Functional Food & Beverages, Others

In 2022, based on application, the infant formula held the highest share of the Human Milk Oligosaccharides (HMO) market.

The global demand for infant formula has been steadily increasing, driven by factors such as urbanization, changing lifestyles, and the rise in the number of working mothers. According to the Babytree/Nielsen research Infant formula makes up the great bulk of the baby care market, accounting for 72% of all sales. With more parents opting for infant formula as an alternative to breastfeeding, the demand for high-quality and nutritionally enriched formulas, including those containing HMOs, has risen significantly.

Infant formula serves as a substitute for breast milk components when breastfeeding is not possible or insufficient. HMOs are an essential component of breast milk, contributing to various health benefits for infants, including supporting the immune system, gut health, and cognitive development. The inclusion of HMOs in infant formula is aimed at providing similar benefits and promoting the growth and development of formula-fed infants.

Geographical Analysis

Growing Health Consciousness in North America Regions

In 2022, the North American region had a significant share of the Human Milk Oligosaccharides (HMO) market. North America has a well-established healthcare infrastructure and advanced research and development capabilities. The region is home to several prominent pharmaceutical and nutrition companies that are actively engaged in HMO research and product development. The strong healthcare infrastructure facilitates the production, distribution, and marketing of HMO-based products, contributing to the region's significant market share.

North America is home to several key market players in the HMO industry, including manufacturers, suppliers, and distributors. These companies have the expertise, resources, and market reach to drive the growth of HMO-based products in the region. The presence of established market players strengthens the market position of North America in the HMO industry.

Competitive Landscape

The major global players in the market include: Elicityl SA, Medolac Laboratories, Inbiose NV, Glycosyn, ZuChem, Jennewein Biotechnologie GmbH, Glycom A/S, Dextra Laboratories Limited, DuPont Nutrition & Health, Nestle Health Science

Why Purchase the Report?

To visualize the global human milk oligosaccharides (HMO) market segmentation based on product, type, application and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of human milk oligosaccharides (HMO) market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The Global Human Milk Oligosaccharides (HMO) Market Report Would Provide Approximately 61 Tables, 63 Figures, and 102 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product
3.2. Snippet by Type
3.3. Snippet by Application
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 7.1.2. Market Attractiveness Index, By Product
7.2. Lacto-N-neotetraose (LNnT) *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Lacto-N-tetraose (LNT)
7.4. 2'-Fucosyllactose (2'FL)
7.5. 3'-Fucosyllactose (3'FL)
7.6. 3'-Sialyllactose (3'SL)
7.7. 6'-Sialyllactose (6'SL)
7.8. Others

8. By Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 8.1.2. Market Attractiveness Index, By Type
8.2. Neutral*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Acidic
8.4. Others

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Infant Formula*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Dietary Supplements
9.4. Functional Food & Beverages
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. The UK
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Elicityl SA*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Medolac Laboratories
12.3. Inbiose NV
12.4. Glycosyn
12.5. ZuChem
12.6. Jennewein Biotechnologie GmbH
12.7. Glycom A/S
12.8. Dextra Laboratories Limited
12.9. DuPont Nutrition & Health
12.10. Nestle Health Science

LIST NOT EXHAUSTIVE